D. Figarella-Branger

D. Figarella-Branger, G. Rougon, P. Bouillot, 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

E. Pasquier, O. Chinot, D. Figarella-Branger, 2022, bioRxiv.

Central Neurocytomas: Critical Evaluation of a Small‐Cell Neuronal Tumor

C. Daumas-Duport, D. Figarella-Branger, G. Rougon, 1992 .

Erratum to: Epidemiology for primary brain tumors: a nationwide population-based study

H. Duffau, D. Figarella-Branger, B. Trétarre, 2016, Journal of Neuro-Oncology.

Expression of the members of the Ptx family of transcription factors in human pituitary adenomas.

D. Figarella-Branger, A. J. Zamora, M. Grino, 1999, The Journal of clinical endocrinology and metabolism.

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

P. Chanson, D. Figarella-Branger, R. Assaker, 2010, The Journal of clinical endocrinology and metabolism.

Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders.

D. Figarella-Branger, E. Malfatti, N. Romero, 2013, Journal of neuropathology and experimental neurology.

Malignant transformation of an osteoblastoma of the skull: an exceptional occurrence. Case report.

L. Garbe, D. Figarella-Branger, J. Hassoun, 1991, Journal of neurosurgery.

Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature.

D. Figarella-Branger, C. Colin, L. Ouafik, 2009, Brain : a journal of neurology.

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial

David T. W. Jones, P. Raman, S. Pfister, 2018, Cancer cell.

Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma

D. Figarella-Branger, R. Berges, D. Braguer, 2018, Cell Death & Disease.

Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines

O. Chinot, D. Figarella-Branger, G. Rougon, 2010, BMC Cancer.

Measuring the contribution of tumor biobanks to research in oncology: surrogate indicators and bibliographic output.

A. Cambon-Thomsen, Georges Dagher, B. Parodi, 2013, Biopreservation and biobanking.

Expression of peptide-23/pancreatitis-associated protein and Reg genes in human pituitary and adenomas: comparison with other fetal and adult human tissues.

D. Figarella-Branger, C. Figarella, I. Pellegrini, 1998, The Journal of clinical endocrinology and metabolism.

Can histologically normal epileptogenic zone share common electrophysiological phenotypes with focal cortical dysplasia? SEEG-based study in MRI-negative epileptic patients

F. Bartolomei, A. Staack, B. Lhermitte, 2019, Journal of Neurology.

Sequence of expression of MyoD1 and various cell surface and cytoskeletal proteins in regenerating mouse muscle fibers following treatment with sodium dihydrogen phosphate

D. Figarella-Branger, J. Pellissier, G. Karpati, 1999, Journal of the Neurological Sciences.

Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.

A. Tabarin, D. Figarella-Branger, G. Rougon, 2003, Journal of neurosurgery.

Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases.

J. Peragut, J. Régis, D. Figarella-Branger, 1996, Neurosurgery.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs

Roland Eils, Pieter Wesseling, Martin Sill, 2016, Cell.

Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis.

D. Figarella-Branger, D. Ellison, J. Grill, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microarray Analysis Reveals Differential Gene Expression Patterns in Tumors of the Pineal Region

C. Mottolese, A. Jouvet, J. Lachuer, 2006, Journal of neuropathology and experimental neurology.

Pineocytoma and Pineal Parenchymal Tumors of Intermediate Differentiation Presenting Cytologic Pleomorphism: A Multicenter Study

P. Varlet, A. Jouvet, D. Figarella-Branger, 2008, Brain pathology.

Central Neurocytoma: A Synopsis of Clinical and Histological Features

P. Kleihues, D. Figarella-Branger, F. Söylemezoğlu, 1993, Brain pathology.

[French brain tumor database: general results on 40,000 cases, main current applications and future prospects].

D. Figarella-Branger, P. Fabbro-Péray, B. Trétarre, 2012, Neuro-Chirurgie.

The contribution of cytogenetics to the histogenesis of meningeal hemangiopericytoma

D. Figarella-Branger, N. Graziani, F. Grisoli, 1996, Journal of Neuro-Oncology.

Predominance of sialomucin secretion in malignant and premalignant pancreatic lesions.

L. Xerri, D. Figarella-Branger, H. Sarles, 1990, Human pathology.

Correlation between laminin and Type IV collagen distribution in Breast Carcinomas, and Estrogen receptors expression, Lymph Node and Vascular involvement

L. Xerri, D. Figarella-Branger, P. Casanova, 1990, Medical oncology and tumor pharmacotherapy.

Adult onset reducing body myopathy

D. Figarella-Branger, J. Pouget, M. Fardeau, 1999, Neuromuscular Disorders.

Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors.

D. Figarella-Branger, G. Rougon, P. Durbec, 1990, Cancer research.

Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs.

D. Figarella-Branger, A. Barlier, T. Graillon, 2014, The Journal of clinical endocrinology and metabolism.

Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells.

D. Figarella-Branger, A. Barlier, H. Dufour, 2012, Human gene therapy.

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.

D. Figarella-Branger, A. Barlier, H. Dufour, 2008, Cancer research.

Resistance of Human Pituitary Adenomas Hormonal Hypersecretion and Reverses Octreotide Somatostatin Receptor sst 2 Decreases Cell Viability and

D. Figarella-Branger, A. Barlier, H. Dufour, 2008 .

Somatostatin Receptor sst 2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas

D. Figarella-Branger, A. Barlier, H. Dufour, 2008 .

Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas.

D. Figarella-Branger, A. Barlier, A. J. Zamora, 1998, The Journal of clinical endocrinology and metabolism.

Prognostic impact of O6‐methylguanine‐DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

O. Chinot, D. Figarella-Branger, L. Ouafik, 2009, Cancer.

Exclusive Hyper-fractionated Radiotherapy and reduced boost volume for standard-risk medulloblastoma: pooled analysis of the two French multicentric studies MSFOP98 and MSFOP 2007 and correlation with molecular subgroups.

B. Dubray, D. Figarella-Branger, P. Bondiau, 2020, International journal of radiation oncology, biology, physics.

Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.

N. André, D. Figarella-Branger, L. Guerrini-Rousseau, 2020, Neuro-oncology.

SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution.

D. Figarella-Branger, E. Tabouret, M. Krummel, 2020, Cell metabolism.

LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene.

J. Emparanza, D. Figarella-Branger, C. Bönnemann, 2005, Brain : a journal of neurology.

A TPM3 mutation causing cap myopathy

D. Figarella-Branger, J. Pouget, N. Monnier, 2009, Neuromuscular Disorders.

Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia

D. Figarella-Branger, J. Pouget, M. Krahn, 2006, Neurology.

Central nervous system disease in patients with macrophagic myofasciitis.

D. Ranoux, J. Degos, D. Figarella-Branger, 2001, Brain : a journal of neurology.

[Slowly progressive myopathy with accumulation of tubular aggregates].

G. Serratrice, D. Figarella-Branger, J. Pouget, 1991, Revue neurologique.

Molecular heterogeneity of glioblastomas: does location matter?

O. Chinot, D. Figarella-Branger, C. Colin, 2015, Oncotarget.

Cortical and Subventricular Zone Glioblastoma-Derived Stem-Like Cells Display Different Molecular Profiles and Differential In Vitro and In Vivo Properties

F. Ducray, D. Figarella-Branger, G. Rougon, 2012, Annals of Surgical Oncology.

Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.

D. Figarella-Branger, C. Colin, C. Bouvier, 2011, Revue neurologique.

Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution

O. Chinot, D. Figarella-Branger, C. Colin, 2011, Annals of Surgical Oncology.

[Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment].

D. Figarella-Branger, C. Colin, C. Bouvier, 2010, Neuro-Chirurgie.

An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients

Jean-Yves Delattre, Jérôme Honnorat, François Ducray, 2010, Molecular Cancer.

PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas

F. Ducray, D. Figarella-Branger, R. Appay, 2019, Neuro-Oncology.

Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

David C. Jones, S. Yip, B. Tops, 2022, Acta Neuropathologica.

Magnetic Resonance Metabolic Imaging of Glioma

D. Figarella-Branger, P. Metellus, 2012, Science Translational Medicine.

Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells

D. Figarella-Branger, F. Helmbacher, F. Conti, 2016, Oncotarget.

Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults

F. Ducray, M. Gabut, J. Honnorat, 2021, Neuro-oncology advances.

Epidemiology for primary brain tumors: a nationwide population-based study

H. Duffau, D. Figarella-Branger, B. Trétarre, 2017, Journal of Neuro-Oncology.

A2B5 Cells from Human Glioblastoma have Cancer Stem Cell Properties

D. Figarella-Branger, M. Cayre, C. Colin, 2010, Brain pathology.

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

H. Lane, A. Sergé, D. Figarella-Branger, 2020, Oncotarget.

Tau Regulates Glioblastoma Progression, 3D Cell Organization, Growth and Migration via the PI3K-AKT Axis

D. Figarella-Branger, H. Kovacic, G. Breuzard, 2021, Cancers.

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co‐deleted anaplastic gliomas

C. Duyckaerts, F. Ducray, Y. Marie, 2017, Brain pathology.

Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma

D. Figarella-Branger, R. Berges, D. Braguer, 2018, Cell Death & Disease.

cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading

Pieter Wesseling, Christine Haberler, Arie Perry, 2020, Brain pathology.

Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14

M. Kool, S. Pfister, E. Aronica, 2019, Neuropathology and applied neurobiology.

cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates

Pieter Wesseling, Arie Perry, Andreas von Deimling, 2019, Brain pathology.

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

Pieter Wesseling, Caterina Giannini, David N. Louis, 2018, Acta Neuropathologica.

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)

D. Louis, P. Wesseling, W. Wick, 2018, Acta Neuropathologica.

Co‐occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma

P. Varlet, N. Boddaert, D. Figarella-Branger, 2018, Brain pathology.

International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

Pieter Wesseling, Arie Perry, Caterina Giannini, 2014, Brain pathology.

Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts

Richard G Grundy, Jacques Grill, Mehmet Kocak, 2011, Journal of Negative Results in BioMedicine.

Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients

M. Sanson, J. Honnorat, O. Chinot, 2012, Cancer.

Correction: SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas

F. Ducray, J. Honnorat, O. Chinot, 2013, PLoS ONE.

Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion

P. Varlet, D. Figarella-Branger, C. Godfraind, 2023, Acta Neuropathologica Communications.

High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts.

E. Mandonnet, M. Sanson, P. Varlet, 2020, Neuro-oncology.

[Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].

D. Figarella-Branger, C. Colin, C. Bouvier, 2013, Bulletin du cancer.

Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse

N. André, S. Pfister, T. Jacques, 2021, Neuro-oncology.

Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas

D. Figarella-Branger, A. Korshunov, R. Appay, 2018, Modern Pathology.

A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

D. Figarella-Branger, R. Assaker, C. Maurage, 2013, Acta Neuropathologica.

A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.

J. Lachuer, D. Figarella-Branger, A. Wierinckx, 2007, Endocrine-related cancer.

Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database

E. Mandonnet, P. Cornu, P. Varlet, 2016, Neuro-oncology.

CD44H is Expressed by cells of the Oligodendrocyte Lineage and by Oligodendrogliomas in Humans

D. Figarella-Branger, A. Liprandi, C. Bouvier-Labit, 2002, Journal of Neuro-Oncology.

The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling.

D. Figarella-Branger, J. Drouin, A. Balsalobre, 2012, Genes & development.

Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening.

O. Chinot, D. Figarella-Branger, P. Metellus, 2014, Experimental cell research.

MALDI imaging and in‐source decay for top‐down characterization of glioblastoma

O. Chinot, D. Figarella-Branger, L. Ouafik, 2014, Proteomics.

DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression

D. Figarella-Branger, M. Junier, P. Lagadec, 2018, Oncogene.

Congenital Rapidly Fatal Form of Nemaline Myopathy with Fetal Hydrops and Arthrogryposis

D. Figarella-Branger, L. Boubli, D. Vardon, 1998, Fetal Diagnosis and Therapy.

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide

Y. Marie, M. Sanson, J. Mosser, 2014, PloS one.

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

M. Sanson, J. Mosser, P. Dubus, 2014, Journal of Neuro-Oncology.

A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process

D. Figarella-Branger, G. Rougon, E. Gautherot, 2001, Oncogene.

Molecular Characterization of Adult Tumors Diagnosed as Cerebellar Glioblastomas Identifies Subgroups Associated With Prognosis

F. Ducray, M. Gabut, D. Figarella-Branger, 2022, The American journal of surgical pathology.

EWSR1‐PATZ1 gene fusion may define a new glioneuronal tumor entity

David T. W. Jones, D. Figarella-Branger, F. Roux, 2018, Brain pathology.

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.

O. Chinot, D. Figarella-Branger, E. Tabouret, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.

R. Schwarzenbacher, D. Figarella-Branger, C. La Morgia, 2008, Brain : a journal of neurology.

Rosette‐forming glioneuronal tumours are midline, FGFR1‐mutated tumours

P. Varlet, B. Lhermitte, D. Figarella-Branger, 2022, Neuropathology and applied neurobiology.

SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas

F. Ducray, J. Honnorat, O. Chinot, 2012, PloS one.

Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.

J. Lachuer, D. Figarella-Branger, A. Wierinckx, 2010, The Journal of clinical endocrinology and metabolism.

Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice

D. Figarella-Branger, G. Rougon, H. Luche, 2016, Scientific Reports.

CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle

D. Figarella-Branger, G. Rougon, H. Moreau, 2004, Acta Neuropathologica.

Comprehensive genome characterization of solitary fibrous tumors using high‐resolution array‐based comparative genomic hybridization

F. Bertucci, D. Birnbaum, P. Finetti, 2013, Genes, chromosomes & cancer.

Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies

D. Figarella-Branger, Dominique Figarella‐Branger, Muriel Civatte, 2003, Muscle & nerve.

Massive inflammatory syndrome and lymphocytic immunodeficiency in KARAP/DAP12‐transgenic mice

D. Figarella-Branger, É. Vivier, S. Guia, 2002, European journal of immunology.

Stereoelectroencephalography in presurgical assessment of MRI-negative epilepsy.

Fabrice Bartolomei, Patrick Chauvel, Martine Gavaret, 2007, Brain : a journal of neurology.

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas

F. Ducray, Y. Marie, M. Sanson, 2014, BioMed research international.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial

D. Figarella-Branger, T. Pietsch, S. Rutkowski, 2018, The Lancet. Oncology.

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group.

S. Pfister, D. Figarella-Branger, S. Puget, 2018, The Lancet. Oncology.

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

T. Björk-Eriksson, G. Gustafsson, D. Figarella-Branger, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic study of six cases of radiation-induced meningiomas.

D. Figarella-Branger, H. Dufour, P. Roll, 2001, Cancer genetics and cytogenetics.

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial

G. Gustafsson, D. Figarella-Branger, T. Pietsch, 2015, Oncotarget.

Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis

P. Varlet, D. Figarella-Branger, S. Puget, 2018, Brain pathology.

WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial

P. Varlet, T. Jacques, D. Figarella-Branger, 2019, Neuro-oncology.

Expression of integrin alpha6beta1 enhances tumorigenesis in glioma cells.

D. Figarella-Branger, L. Ouafik, S. Mathieu, 2009, The American journal of pathology.

SOLITARY FIBROUS TUMORS OF THE CENTRAL NERVOUS SYSTEM: CLINICOPATHOLOGICAL AND THERAPEUTIC CONSIDERATIONS OF 18 CASES

A. Jouvet, D. Figarella-Branger, H. Dufour, 2007, Neurosurgery.

Gene Expression Profiling of Solitary Fibrous Tumors

F. Bertucci, D. Birnbaum, P. Finetti, 2013, PloS one.

HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases

M. Kool, N. André, D. Figarella-Branger, 2017, The American journal of surgical pathology.

Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice

D. Figarella-Branger, G. Rougon, L. Maggiorella, 2014, Oncogene.

Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases

David T. W. Jones, P. Varlet, D. Figarella-Branger, 2020, Acta Neuropathologica Communications.

Somatotroph Tumors and the Epigenetic Status of the GNAS Locus

D. Figarella-Branger, G. Assié, A. Barlier, 2021, International journal of molecular sciences.

Gsα overexpression and loss of Gsα imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment

J. Gabert, D. Figarella-Branger, A. Barlier, 2007, International journal of cancer.

A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood ( 16 years ) low grade glioma e A final report

K. Skullerud, T. Egeland, D. Machin, 2017 .

Acrocallosal syndrome in fetus: focus on additional brain abnormalities

C. Fallet-Bianco, D. Figarella-Branger, F. Giuliano, 2007, Acta Neuropathologica.

Prognostic factors in intracranial ependymomas in children.

D. Figarella-Branger, M. Choux, J. Gouvernet, 2000, Journal of neurosurgery.

Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors

David T. W. Jones, D. Figarella-Branger, A. Korshunov, 2016, Oncotarget.

Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAFV600E Mutation and Expression

D. Figarella-Branger, C. Colin, A. Loundou, 2013, Brain pathology.

Search for distinctive markers in DNT and cortical grade II glioma in children: same clinicopathological and molecular entities?

D. Birnbaum, D. Figarella-Branger, N. Girard, 2012, Current topics in medicinal chemistry.

Clinical epidemiology for childhood primary central nervous system tumors

H. Duffau, P. Coubes, D. Figarella-Branger, 2009, Journal of Neuro-Oncology.

Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy

O. Chinot, D. Figarella-Branger, R. Appay, 2022, Journal of the Neurological Sciences.

Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas

D. Figarella-Branger, K. Pacak, A. Barlier, 2016, Journal of Neuro-Oncology.

Adrenomedullin as a therapeutic target in angiogenesis

S. Salas, D. Figarella-Branger, L. Ouafik, 2010, Expert opinion on therapeutic targets.

Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution

N. André, D. Figarella-Branger, C. Colin, 2013, Neuropathology and applied neurobiology.

Papillary glioneuronal tumour: clinicopathological and biochemical study of one case with 7-year follow up

D. Figarella-Branger, H. Dufour, F. Grisoli, 2000, Acta Neuropathologica.

A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells*

D. Figarella-Branger, M. Junier, T. Virolle, 2016, The Journal of Biological Chemistry.

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells

H. Lane, D. Figarella-Branger, R. Berges, 2016, Molecular Cancer Therapeutics.

Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients.

O. Chinot, A. Jouvet, D. Figarella-Branger, 2007, Brain : a journal of neurology.

Fetal brain injury.

D. Figarella-Branger, P. Cozzone, N. Girard, 2004, Journal of neuroradiology. Journal de neuroradiologie.

31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies

G Serratrice, G. Serratrice, D. Figarella-Branger, 1992, Neurology.

Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway

O. Chinot, D. Figarella-Branger, E. Tabouret, 2015, Oncotarget.

Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

K. Hoang-Xuan, Y. Marie, O. Chinot, 2012, Clinical Cancer Research.

A monoclonal antibody against Meningococcus group B polysaccharides used to immunocapture and quantify polysialylated NCAM in tissues and biological fluids.

D. Figarella-Branger, G. Rougon, C. Dubois, 1995, Journal of immunological methods.

Expression of various isoforms of neural cell adhesive molecules and their highly polysialylated counterparts in diseased human muscles

D. Figarella-Branger, G. Rougon, J. Pellissier, 1990, Journal of the Neurological Sciences.

Myopathy with hexagonally cross-linked crystalloid inclusions: Delineation of a clinico-pathological entity

K. Claeys, D. Figarella-Branger, H. Goebel, 2010, Neuromuscular Disorders.

Inflammatory and non-inflammatory inclusion body myositis

D. Figarella-Branger, J. Pellissier, B. Devictor, 1990, Acta Neuropathologica.

Muscular Metabolism and Contraction in Exertional Heat Stroke

D. Figarella-Branger, P. Cozzone, D. Bendahan, 1999 .

Rs488087 single nucleotide polymorphism as predictive risk factor for pancreatic cancers

D. Figarella-Branger, J. Iovanna, F. Barlesi, 2015, Oncotarget.

Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice

Christophe Dussert, Pierre-Marie Martin, Philippe Metellus, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Mitochondrial DNA copy number as a prognostic marker is age-dependent in adult glioblastoma

M. Sanson, D. Figarella-Branger, C. Bris, 2022, Neuro-oncology advances.

Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma

F. Scaravilli, I. Salmon, T. Palm, 2007, Molecular Cancer.

Expression of cell surface and cytoskeleton developmentally regulated proteins in adult centronuclear myopathies

D. Figarella-Branger, G. Rougon, J. Pellissier, 1992, Journal of the Neurological Sciences.

Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies

H. Lepidi, D. Figarella-Branger, J. Pellissier, 1999, Acta Neuropathologica.

Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility

J. Payen, P. Mezin, D. Figarella-Branger, 2005, Human mutation.

Histopathological observations on vestibular schwannomas after Gamma Knife radiosurgery: the Marseille experience.

J. Régis, J. Régis, D. Figarella-Branger, 2004, Neuro-Chirurgie.

Atypical teratoid/rhabdoid tumour: 7-year event-free survival with gross total resection and radiotherapy in a 7-year-old boy

D. Figarella-Branger, A. M. Paula, C. Bouvier, 2007, Child's Nervous System.

Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: Identification of 10 new mutations. Absence of genotype–phenotype correlation

G. Serratrice, D. Figarella-Branger, J. Pouget, 2007, Neuromuscular Disorders.

Exertional rhabdomyolysis and exercise intolerance revealing dystrophinopathies

D. Figarella-Branger, J. Pellissier, P. Malzac, 1997, Acta Neuropathologica.

Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies.

C. Fallet-Bianco, D. Figarella-Branger, A. Laquérriere, 2012, Brain : a journal of neurology.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

S. Truant, M. Ychou, P. Colombo, 2018, BMC Cancer.

Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA.

D. Figarella-Branger, C. Huxley, M. Fontès, 1996, Human molecular genetics.

Do the suprasellar neurenteric cyst, the Rathke cleft cyst and the colloid cyst constitute a same entity?

D. Figarella-Branger, H. Dufour, A. Donnet, 2005, Acta Neurochirurgica.

Improving molecular diagnosis of distal myopathies by targeted next-generation sequencing

Christophe Béroud, Svetlana Gorokhova, Mathieu Cerino, 2015, Journal of Neurology, Neurosurgery & Psychiatry.

Expanding the clinical spectrum of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis due to FAM111B mutations

A. Munnich, D. Figarella-Branger, S. Küry, 2015, Orphanet Journal of Rare Diseases.

Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis.

R. Redon, A. Munnich, B. Keavney, 2013, American journal of human genetics.

Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.

V. Esposito, D. Figarella-Branger, G. Occhi, 2013, Endocrine-related cancer.

Pit-1 gene expression in the human pituitary and pituitary adenomas.

D. Figarella-Branger, A. Barlier, I. Pellegrini, 1994, The Journal of clinical endocrinology and metabolism.

Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene

D. Figarella-Branger, J. Pouget, N. Lévy, 2003, Neurology.

Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB

S. Fulda, D. Figarella-Branger, S. Momma, 2014, Cell Death and Differentiation.

Translocation 1;19 in two brain tumors.

D. Figarella-Branger, F. Mugneret, J. Bernard, 1997, Cancer genetics and cytogenetics.

Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome

Caterina Giannini, Ping-Pin Zheng, Felice Giangaspero, 2007, Journal of neuropathology and experimental neurology.

Genesis and biology of vestibular schwannomas.

O. Chinot, D. Figarella-Branger, C. Bouvier, 2008, Progress in neurological surgery.

Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study

H. Duffau, E. Mandonnet, D. Figarella-Branger, 2018, Journal of Neuro-Oncology.

Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.

H. Duffau, L. Capelle, J. Honnorat, 2010, Neuro-oncology.

TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma

David T. W. Jones, S. Pfister, D. Figarella-Branger, 2016, Oncotarget.

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas

F. Ducray, M. Sanson, O. Chinot, 2019, Acta Neuropathologica Communications.

[Primary leiomyosarcoma of the cavernous sinus associated with Epstein-Barr virus in a kidney graft].

A. Eusebio, D. Figarella-Branger, T. Witjas, 2003, Revue neurologique.

Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

O. Chinot, A. Jouvet, D. Figarella-Branger, 2010, Neuro-oncology.

Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016

J. Mosser, O. Chinot, D. Figarella-Branger, 2019, Journal of Neuro-Oncology.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome

F. Ducray, O. Chinot, A. Idbaih, 2018, Acta Neuropathologica Communications.

Specific and Sensitive Diagnosis of BCOR-ITD in Various Cancers by Digital PCR

P. Varlet, D. Figarella-Branger, R. Appay, 2021, Frontiers in Oncology.

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

W. Mason, A. Brandes, O. Chinot, 2022, Acta neuropathologica communications.

An AI-Powered Blood Test to Detect Cancer Using NanoDSF

Dominique Figarella-Branger, Philipp O. Tsvetkov, R'emi Eyraud, 2020, bioRxiv.

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool

P. Tsvetkov, O. Chinot, D. Figarella-Branger, 2018, Oncotarget.

Differential Diagnosis of Meningeal SFT-HPC and Meningioma: Which Immunohistochemical Markers Should Be Used?

A. Jouvet, D. Figarella-Branger, A. Loundou, 2015, The American journal of surgical pathology.

Multiparametric differentiation of posterior fossa tumors in children using diffusion‐weighted imaging and short echo‐time 1H‐MR spectroscopy

D. Figarella-Branger, P. Cozzone, N. Girard, 2007, Journal of magnetic resonance imaging : JMRI.

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Pierre-Marie Martin, Sophie Lancelot, Diane Braguer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diffuse gliomas with FGFR 3-TACC 3 fusion have characteristic histopathological and molecular features

Mokhtari, A. Iavarone, M. Sanson, 2019 .

Diffuse gliomas with FGFR3‐TACC3 fusion have characteristic histopathological and molecular features

A. Iavarone, M. Sanson, D. Figarella-Branger, 2018, Brain pathology.

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system

O. Chinot, D. Figarella-Branger, C. Colin, 2012, Journal of Neuro-Oncology.

A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas

A. Iavarone, Y. Marie, M. Sanson, 2018, Nature Communications.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial

F. Ducray, M. Sanson, O. Chinot, 2016, Oncotarget.

A polyphenotypic malignant paediatric brain tumour presenting a MN1‐PATZ1 fusion, no epigenetic similarities with CNS High‐Grade Neuroepithelial Tumour with MN1 Alteration (CNS HGNET‐MN1) and related to PATZ1‐fused sarcomas

D. Figarella-Branger, C. Godfraind, C. Maurage, 2020, Neuropathology and applied neurobiology.

Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2

F. Chibon, S. Salas, D. Figarella-Branger, 2009, International journal of cancer.

Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.

David Taieb, Philippe Metellus, D. Figarella-Branger, 2016, Oncotarget.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo

O. Chinot, D. Figarella-Branger, A. Kruczynski, 2014, Oncotarget.

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

O. Chinot, D. Figarella-Branger, E. Guedj, 2012, Neuro-oncology.

CD44s and CD44v6 expression in localized T1–T2 conventional renal cell carcinomas

D. Figarella-Branger, V. Lindner, R. Giorgi, 2001, The Journal of pathology.

Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy

Damien Galanaud, Yann Le Fur, François Nicoli, 2006, Magnetic resonance in medicine.

Cavernous angiomas and arteriovenous malformations of the spinal epidural space: report of 11 cases.

D. Figarella-Branger, H. Dufour, P. Bouillot, 1994, Neurosurgery.

ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study

F. Bertucci, D. Birnbaum, P. Finetti, 2013, Acta Neuropathologica Communications.

Mutational analysis of primary central nervous system lymphoma

K. Hoang-Xuan, Y. Marie, A. Jouvet, 2014, Oncotarget.

Dystrophinopathies and CPT Deficiency in 75 Patients with Exertional Heat Stroke and Rhabdomyolysis

G. Serratrice, D. Figarella-Branger, P. Cozzone, 1999 .

Infratentorial pediatric brain tumors: the value of new imaging modalities.

D. Figarella-Branger, S. Confort-Gouny, P. Cozzone, 2007, Journal of neuroradiology. Journal de neuroradiologie.

Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy.

D. Figarella-Branger, G. Rougon, J. Trouillas, 2000, Cancer research.

Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152

D. Figarella-Branger, C. Colin, A. El-Battari, 2016, Cell Death and Disease.

[Meningeal hemangiopericytomas. A retrospective reciew of 20 cases].

J. Régis, D. Figarella-Branger, H. Dufour, 1998, Neuro-chirurgie.

OS8.7 Targeting Pi3k-Akt-mTOR and MAPKinase pathways in aggressive meningiomas: in vitro study

D. Figarella-Branger, A. Barlier, H. Dufour, 2019, Neuro-Oncology.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort

F. Ducray, O. Chinot, A. Idbaih, 2016, Acta Neuropathologica.

Chordoid Gliomas of the Third Ventricle Share TTF-1 Expression With Organum Vasculosum of the Lamina Terminalis

Charles Duyckaerts, C. Duyckaerts, M. Sanson, 2015, The American journal of surgical pathology.

Differential expression of cell adhesion molecules (CAM), neural CAM and epithelial cadherin in ependymomas and choroid plexus tumors

H. Lepidi, D. Figarella-Branger, G. Rougon, 2004, Acta Neuropathologica.

[Acoustico-facial cavernomas. Apropos of 2 surgically treated cases].

D. Figarella-Branger, W. Pellet, P. Roche, 1997, Neuro-Chirurgie.

Surgical resection of brain metastases from breast cancer in the modern era: clinical outcome and prognostic factors.

Emeline Tabouret, Philippe Metellus, D. Figarella-Branger, 2013, Anticancer research.

High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas

O. Chinot, J. Kos, D. Figarella-Branger, 2009, Acta Neuropathologica.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs

Volker Hovestadt, Stefan M. Pfister, Brent A. Orr, 2016, Cell.

CNS neuroblastoma, FOXR2-activated and its mimics: a relevant panel approach for work-up and accurate diagnosis of this rare neoplasm

P. Varlet, B. Lhermitte, D. Figarella-Branger, 2023, Acta Neuropathologica Communications.

Cytogenetic study of 33 ependymomas.

D. Figarella-Branger, M. Choux, H. Dufour, 1999, Cancer genetics and cytogenetics.

Mixed meningeal and brain plasma-cell granuloma: an example of an unusual evolution

D. Figarella-Branger, W. Pellet, P. Roche, 2004, Acta Neurochirurgica.

Primary intracerebral plasma cell granuloma: a light, immunocytochemical, and ultrastructural study of one case.

L. Garbe, D. Figarella-Branger, F. Grisoli, 1990, Neurosurgery.

De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors

P. Varlet, D. Figarella-Branger, F. Bielle, 2018, Neuro-oncology.

Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.

D. Figarella-Branger, J. Grill, P. Maingon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ectopic intrapelvic medulloepithelioma: case Report

D. Figarella-Branger, J. Gentet, J. Pellissier, 1992, Neuropathology and applied neurobiology.

The usefulness of MR imaging in the diagnosis of dysembryoplastic neuroepithelial tumor in children: a study of 14 cases.

D. Figarella-Branger, N. Girard, C. Fernandez, 2003, AJNR. American journal of neuroradiology.

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High‐Grade Gliomas with Necrosis

P. Varlet, A. Jouvet, D. Figarella-Branger, 2015, Brain pathology.

Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas

O. Chinot, D. Figarella-Branger, E. Guedj, 2012, Journal of Neuro-Oncology.

Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization

D. Figarella-Branger, C. Colin, L. Ouafik, 2006, Oncogene.

The French glioblastoma biobank (FGB): a national clinicobiological database

B. Chauffert, F. Ducray, M. Sanson, 2019, Journal of Translational Medicine.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

F. Ducray, M. Sanson, O. Chinot, 2017, Cancer biomarkers : section A of Disease markers.

Prognostic Factors in Central Neurocytomas: A Multicenter Study of 71 Cases

A. Jouvet, D. Figarella-Branger, A. Loundou, 2012, The American journal of surgical pathology.

The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types

Badih Ghattas, Sylviane Confort-Gouny, Nadine Girard, 2016, Journal of Neuro-Oncology.

Utility of Ki67 immunostaining in the grading of pineal parenchymal tumours: a multicentre study

D. Frappaz, A. Jouvet, D. Figarella-Branger, 2012, Neuropathology and applied neurobiology.

Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France

H. Duffau, L. Capelle, F. Ducray, 2014, Neurosurgical Review.

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

O. Chinot, D. Figarella-Branger, D. Braguer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases

D. Figarella-Branger, N. Girard, C. Colin, 2006, Child's Nervous System.

Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

F. Ducray, A. Idbaih, A. Jouvet, 2014, Neuro-oncology.

Meningeal Rosai–Dorfman disease mimicking meningioma

D. Figarella-Branger, P. Metellus, A. M. Paula, 2013, Annals of Hematology.

Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies

A. Delacourte, D. Figarella-Branger, N. Sergeant, 2004, Neuropathology and applied neurobiology.

Familial desmin myopathies and cytoplasmic body myopathies

H. Lepidi, D. Figarella-Branger, J. Pellissier, 1996, Acta Neuropathologica.

Epileptogenic brain lesions in children: the added-value of combined diffusion imaging and proton MR spectroscopy to the presurgical differential diagnosis

D. Figarella-Branger, S. Confort-Gouny, P. Cozzone, 2012, Child's Nervous System.

[Histological and molecular classification of gliomas].

D. Figarella-Branger, C. Colin, B. Coulibaly, 2008, Revue neurologique.

An Epidemiology Report for Primary Central Nervous System Tumors in Adolescents and Young Adults: a nationwide population-based study in France, 2008-2013.

D. Frappaz, D. Figarella-Branger, T. Roujeau, 2019, Neuro-oncology.

Expression of NCAM and its polysialylated isoforms during mdx mouse muscle regeneration and in vitro myogenesis

D. Figarella-Branger, G. Rougon, C. Dubois, 1994, Neuromuscular Disorders.

Molecular heterogeneity in fetal forms of type II lissencephaly

M Joubert, C. Fallet-Bianco, D. Figarella-Branger, 2007, Human mutation.

Sequence of expression of MyoD1 and various cell surface and cytoskeletal proteins in regenerating mouse muscle fibers following treatment with sodium dihydrogen phosphate

D. Figarella-Branger, J. Pellissier, G. Karpati, 1999, Journal of the Neurological Sciences.

Value of fetal autopsy after medical termination of pregnancy.

D. Figarella-Branger, P. Adalian, S. Sigaudy, 2004, Forensic science international.

Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies

B. Chetaille, D. Figarella-Branger, N. Schleinitz, 2005, Neuropathology and applied neurobiology.

The new WHO classification of human pituitary tumors: comments

D. Figarella-Branger, J. Trouillas, 2005, Acta Neuropathologica.

Non‐lethal neonatal neuromuscular variant of glycogenosis type IV with novel GBE1 mutations

D. Figarella-Branger, R. Froissart, A. D. de Paula, 2009, Muscle & nerve.

Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system

K. Baumstarck, D. Figarella-Branger, K. Pacak, 2018, Journal of psychosocial oncology.

Polysialylated-Neural Cell Adhesion Molecule Expression in Rat Pituitary Transplantable Tumors ( Spontaneous Mammotropic Transplantable Tumor in WistarFurth WistarFurth WistarFurth Rats ) Is Related to Growth Rate and Malignancy 1

D. Figarella-Branger, G. Rougon, J. Trouillas, 2000 .

Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma.

O. Chinot, D. Figarella-Branger, C. Colin, 2011, European journal of cancer.

Cell‐adhesion molecules in human meningiomas: correlation with clinical and morphological data

D. Figarella-Branger, J. Pellissier, H. Dufour, 1997, Neuropathology and applied neurobiology.

Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy.

F. Bartolomei, L. Martinian, S. Sisodiya, 2012, Brain : a journal of neurology.

[Synovial cyst of cervical spine].

J. Peragut, D. Figarella-Branger, F. Chaoui, 2000, Neuro-Chirurgie.

Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma

O. Chinot, D. Figarella-Branger, E. Tabouret, 2016, Journal of Neuro-Oncology.

Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients

P. Wesseling, D. Figarella-Branger, B. Küsters, 2019, Brain pathology.

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers

S. Msika, T. Conroy, M. Copin, 2018, BMC Cancer.

Further heterogeneity in myopathy with tubular aggregates?

D. Figarella-Branger, J. Pouget, N. Lévy, 2012, Muscle & nerve.

Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis

D. Figarella-Branger, C. Colin, C. Bouvier, 2007, Neuropathology and applied neurobiology.

Polymyalgia rheumatica and mitochondrial myopathy: clinicopathologic and biochemical studies in five cases.

D. Figarella-Branger, C. Desnuelle, P. Disdier, 1992, The American journal of medicine.

Monitoring therapeutic monoclonal antibodies in brain tumor

O. Chinot, D. Figarella-Branger, L. Ouafik, 2014, mAbs.

Mononeuropathie multiple et anticorps anti-Ma2

J. Honnorat, D. Figarella-Branger, P. Labauge, 2008 .

[Ma2 antibody and multiple mononeuropathies].

J. Honnorat, D. Figarella-Branger, P. Labauge, 2008, Revue neurologique.

Identical twins with macrophagic myofasciitis: genetic susceptibility and triggering by aluminic vaccine adjuvants?

D. Figarella-Branger, F. Nicoli, J. Roudier, 2002, Arthritis and rheumatism.

18F-DOPA, a clinically available PET tracer to study brain inflammation?

Eric Guedj, David Taieb, Philippe Metellus, 2014, Clinical nuclear medicine.

Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear‐cell renal carcinoma

S. Salas, D. Figarella-Branger, J. Mancini, 2009, International journal of cancer.

Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas

J. Gaudart, G. Bollini, S. Salas, 2007, Virchows Archiv.

Real-life clinical impact of a five-tiered classification of pituitary tumors.

J. Régis, D. Figarella-Branger, R. Appay, 2022, European journal of endocrinology.

French brain tumor data bank: Methodology and first results on 10,000 cases

L. Capelle, J. Honnorat, D. Frappaz, 2007, Journal of Neuro-Oncology.

Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma.

Damien Galanaud, Jean-Philippe Ranjeva, Sylviane Confort-Gouny, 2003, Journal of neurosurgery.

Molecular characterization of central neurocytomas: Potential markers for tumor typing and progression

A. Jouvet, D. Figarella-Branger, A. Wierinckx, 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.

SCENITH: A flow cytometry based method for functional profiling energy metabolism with single cell resolution

D. Figarella-Branger, E. Tabouret, M. Krummel, 2020, bioRxiv.

Mutations in CNTNAP1 and ADCY6 are responsible for severe arthrogryposis multiplex congenita with axoglial defects.

I. Gut, M. Bayés, J. Melki, 2014, Human molecular genetics.

Linkage of X-linked myopathy with excessive autophagy (XMEA) to Xq28

D. Figarella-Branger, N. Lévy, J. Chelly, 2000, European Journal of Human Genetics.

Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France

H. Duffau, L. Capelle, D. Figarella-Branger, 2014, Journal of Neuro-Oncology.

GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy

T. Marissal, C. Mulle, D. Figarella-Branger, 2023, bioRxiv.

Prognostic significance of NAB2–STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear

P. Wesseling, D. Figarella-Branger, C. Bouvier, 2019, Acta Neuropathologica.

High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma.

D. Figarella-Branger, C. Bris, V. Desquiret-Dumas, 2019, Neuro-oncology.

MRI and 31PMR spectroscopy investigations of muscle function disclose no abnormality in macrophagic myofasciitis.

D. Figarella-Branger, P. Cozzone, F. Nicoli, 2004, The Journal of rheumatology.

[Role of adrenomedullin in glioblastomas growth].

D. Figarella-Branger, L. Ouafik, Y. Berthois, 2005, Bulletin du Cancer.

Variations in the TRPV1 gene are associated to exertional heat stroke.

D. Figarella-Branger, J. Rendu, S. Ducreux, 2020, Journal of science and medicine in sport.

[Polysaccharide amylopectin-type storage myopathy].

G. Serratrice, D. Figarella-Branger, J. Pouget, 1992, Revue neurologique.

[Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].

D. Figarella-Branger, L. Ouafik, P. Metellus, 2016, Neuro-Chirurgie.

Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies

D. Figarella-Branger, J. Pouget, J. Franques, 2013, Medicine.

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

M. Sanson, O. Chinot, D. Figarella-Branger, 2014, Neuro-oncology.

Expression of developmentally regulated cytoskeleton and cell surface proteins in childhood spinal muscular atrophies

H. Lepidi, D. Figarella-Branger, G. Rougon, 1995, Journal of the Neurological Sciences.

Expression of Various NCAM Isoforms in Human Embryonic Muscles: Correlation with Myosin Heavy Chain Phenotypes

J. Léger, D. Figarella-Branger, G. Rougon, 1992, Journal of neuropathology and experimental neurology.

Correlations between MR and endothelial hyperplasia in low‐grade gliomas

D. Galanaud, D. Figarella-Branger, P. Cozzone, 2007, Journal of magnetic resonance imaging : JMRI.

Dose-Dependent Dual Role of PIT-1 (POU1F1) in Somatolactotroph Cell Proliferation and Apoptosis

D. Figarella-Branger, A. Barlier, T. Graillon, 2015, PloS one.

MR imaging of acquired fetal brain disorders

Sylviane Confort-Gouny, Nadine Girard, Charles Raybaud, 2003, Child's Nervous System.

Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression.

J. Gaudart, O. Chinot, D. Figarella-Branger, 2010, Human pathology.

[Sphenoid sinus lymphoma. Case report and review of the literature].

D. Figarella-Branger, H. Dufour, P. Metellus, 2002, Neuro-chirurgie.

Suprasellar granular-cell tumour, presenting with intraventricular haemorrhage.

D. Figarella-Branger, H. Dufour, P. Bouillot, 1995, British journal of neurosurgery.

Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?

N. André, M. Heng, E. Pasquier, 2016, Cancer medicine.

[Digital necrosis disclosing antisynthetase syndrome].

D. Figarella-Branger, P. Disdier, P. Weiller, 1994, Annales de dermatologie et de venereologie.

[Dermatomyositis and polymyositis].

B. Chetaille, D. Figarella-Branger, N. Schleinitz, 2002, Revue neurologique.

[Inclusion body myositis and neuromuscular diseases with rimmed vacuoles].

G. Serratrice, D. Figarella-Branger, J. Pouget, 1992, Revue neurologique.

Natural history of spinal cord metastasis from brain glioblastomas

E. Mandonnet, D. Figarella-Branger, K. Mokhtari, 2023, Journal of Neuro-Oncology.

Natural Course and Prognosis of Primary Spinal Glioblastoma

A. Jouvet, D. Figarella-Branger, K. Mokhtari, 2023, Neurology.

Fluctuation analysis of postoperative secretory status in patients operated for acromegaly.

D. Figarella-Branger, M. Boucekine, H. Dufour, 2019, Annales d'endocrinologie.

Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo

D. Figarella-Branger, M. Carré, C. Colin, 2014, Oncotarget.

[Lumbar canal stenosis caused by amyloidosis of the yellow ligament].

D. Figarella-Branger, C. Bouvier, W. Pellet, 1999, Neuro-Chirurgie.

Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas.

David T. W. Jones, G. Reifenberger, M. Kool, 2021, Cancer discovery.

[Standards, Options and Recommendations 2002 for the management of adult patients with intracranial gliomas (summary report)].

L. Capelle, M. Sanson, A. Bataillard, 2003, Bulletin du cancer.

Inhibitor of Apoptosis Proteins Determines Glioblastoma Stem‐Like Cell Fate in an Oxygen‐Dependent Manner

D. Figarella-Branger, G. Rougon, H. Kovacic, 2019, Stem cells.

Inhibitor of apoptosis proteins determine glioblastoma stem-like cells fate depending on oxygen level

D. Figarella-Branger, G. Rougon, H. Kovacic, 2018, bioRxiv.

Assessment of cortical maturation with prenatal MRI:Part I. Normal cortical maturation

Nadine Girard, Kathia Chaumoitre, Carla Fernandez, 2005 .

Striking phenotypic variability in two familial cases of myosin storage myopathy with a MYH7 Leu1793pro mutation

D. Figarella-Branger, E. Uro-Coste, T. Levade, 2009, Neuromuscular Disorders.

Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort.

F. Ducray, D. Figarella-Branger, C. Dehais, 2021, The oncologist.

Live Stimulated Raman Histology for the Near-Instant Assessment of Central Nervous System Samples.

H. Rigneault, D. Figarella-Branger, R. Appay, 2023, The journal of physical chemistry. B.

Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma

N. André, D. Figarella-Branger, M. Carré, 2013, Acta neuropathologica communications.

Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006-2010.

D. Figarella-Branger, B. Trétarre, F. Bessaoud, 2015, Neuro-Chirurgie.

escriptive epidemiology of 13 , 038 newly diagnosed and istologically confirmed meningiomas in France : 2006 – 2010 pidémiologie descriptive de 13 038 cas de méningiomes opérés en France entre 006 et 2010

D. Figarella-Branger, B. Trétarre, L. Taillandier, 2015 .

Low‐grade epilepsy‐associated neuroepithelial tumours with a prominent oligodendroglioma‐like component: The diagnostic challenges

L. Riffaud, D. Figarella-Branger, M. Pages, 2021, Neuropathology and applied neurobiology.

[Post-poliomyelitis syndrome: 29 cases].

G. Serratrice, D. Figarella-Branger, J. Pellissier, 1992, Revue neurologique.

CD24, a glycosylphosphatidylinositol-anchored molecule, is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors

D. Figarella-Branger, R. Gristina, J. Pellissier, 1996, Acta Neuropathologica.

Neuroectodermal Tumors Molecule Isoforms and L 1 Adhesion Molecules on Human Differential Spectrum of Expression of Neural Cell Adhesion

D. Figarella-Branger, G. Rougon, P. Durbec, 2006 .

[New foetopathological section of the heart. Correlated to the ultrasonographic 4 Chamber view in fetuses].

D. Figarella-Branger, M. Gonzalès, M. Piercecchi‐Marti, 2006, Annales de pathologie.

A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids with initial normal magnetic resonance imaging.

D. Figarella-Branger, P. Labauge, G. Castelnovo, 2011, Brain : a journal of neurology.

Expression of polysialylated neural cell adhesion molecule (PSA-N-CAM) in developing, adult and regenerating caudal spinal cord of the urodele amphibians.

D. Figarella-Branger, X. Caubit, J. Arsanto, 1993, The International journal of developmental biology.

Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.

D. Figarella-Branger, C. Colin, C. Bouvier, 2003, Journal of neurosurgery.

Adhesion molecules in cancer

D. Figarella-Branger, P. Durbec, G. Rougeon, 1992 .

KIAA0510, the 3′‐untranslated region of the tenascin‐R gene, and tenascin‐R are overexpressed in pilocytic astrocytomas

D. Figarella-Branger, C. Colin, D. Scavarda, 2010, Neuropathology and applied neurobiology.

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas

F. Ducray, D. Figarella-Branger, C. Dehais, 2023, Cancers.

[Prognostic factors in meningiomas].

D. Figarella-Branger, J. Pellissier, A. Liprandi, 2000, Annales de Pathologie.

Myofibrillar myopathies: State of the art, present and future challenges.

I. Nelson, D. Figarella-Branger, N. Romero, 2015, Revue neurologique (Paris).

Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases

David T. W. Jones, P. Varlet, D. Figarella-Branger, 2020, Acta Neuropathologica Communications.

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

E. Pasquier, O. Chinot, D. Figarella-Branger, 2023, EBioMedicine.

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population

O. Chinot, D. Figarella-Branger, A. Barlier, 2018, Front. Oncol..

K. Skullerud, T. Egeland, D. Machin, 2017, European journal of cancer.

Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.

F. Ducray, A. Idbaih, A. Jouvet, 2016, Neuro-oncology.

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.

G. Gustafsson, D. Figarella-Branger, T. Pietsch, 2015, Oncotarget.

Triple-negative, low-grade gliomas: A highly agressive tumor with dismal prognosis.

O. Chinot, D. Figarella-Branger, A. Barlier, 2011, Journal of Clinical Oncology.

Deciphering the Action of Neuraminidase in Glioblastoma Models

D. Figarella-Branger, R. Berges, C. Colin, 2023, International journal of molecular sciences.

[National network of paediatric central nervous system tumours reviewing by the Groupe d'Étude de Neuropathologie Oncologique Pediatrique (GENOP)].

P. Varlet, A. Jouvet, D. Figarella-Branger, 2014, Annales de pathologie.

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline

G. Reifenberger, M. J. van den Bent, B. Tops, 2023, Neuro-oncology.

[Pituitary melanocytoma mimicking an adenoma].

D. Figarella-Branger, H. Dufour, B. Coulibaly, 2011, Annales de pathologie.

[A retrospective study of six patients with late-onset Pompe disease].

D. Figarella-Branger, P. Laforêt, P. Labauge, 2008, Revue neurologique.

Strong Additive Effect of Everolimus and Octreotide or Pasireotide on Meningioma Cells in Vitro: A New Therapeutic Strategy for These Tumors

O. Chinot, D. Figarella-Branger, A. Barlier, 2012 .

Systemic amyloidosis AL with temporal artery involvement revealing lymphoplasmacytic malignancy in a man presenting as polymyalgia rheumatica.

D. Figarella-Branger, P. Lafforgue, P. Acquaviva, 1993, Annals of the rheumatic diseases.

Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility.

D. Figarella-Branger, P. Cozzone, D. Bendahan, 2003, Arthritis and rheumatism.

Local expression of cytokines in idiopathic inflammatory myopathies

Pellissier, H. Lepidi, D. Figarella-Branger, 1998, Neuropathology and applied neurobiology.

Antisynthethase syndrome presenting as peripheral limb fasciitis.

D. Figarella-Branger, J. Harlé, M. Ebbo, 2013, Joint, bone, spine : revue du rhumatisme.

Histopathological grading of intracranial pediatric ependymomas

D. Frappaz, D. Figarella-Branger, D. Ellison, 2008 .

[Horton disease-hyperthyroidism association].

D. Figarella-Branger, P. Disdier, P. Weiller, 1994, Presse medicale.

Phase II study of temozolomide (TMZ) administered on a 7 days on-7 days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM)

J. Peragut, O. Chinot, D. Figarella-Branger, 2005 .

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

G. Reifenberger, D. Louis, P. Kleihues, 2016, Acta Neuropathologica.

Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.

J. Lachuer, D. Figarella-Branger, A. Wierinckx, 2010, The Journal of clinical endocrinology and metabolism.

T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone

F. Ducray, F. Vassal, C. Boutet, 2023, European Journal of Neurology.

Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts

D. Frappaz, D. Figarella-Branger, D. Ellison, 2011, Journal of Negative Results in Biomedicine.

Myofibrillar myopathies: State of the art, present and future challenges.

I. Nelson, D. Figarella-Branger, N. Romero, 2015, Revue neurologique.

Local and remote epileptogenicity in focal cortical dysplasias and neurodevelopmental tumours.

J. Régis, P. Chauvel, F. Bartolomei, 2009, Brain : a journal of neurology.

Spatiotemporal distribution of tenascin‐R in the developing human cerebral cortex parallels neuronal migration

D. Figarella-Branger, A. D. de Paula, N. Baeza, 2011, The Journal of comparative neurology.

Striking phenotypic variability in two familial cases of myosin storage myopathy with a MYH7 Leu1793pro mutation

D. Figarella-Branger, E. Uro-Coste, T. Levade, 2009, Neuromuscular Disorders.

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co‐deleted anaplastic gliomas

C. Duyckaerts, F. Ducray, Y. Marie, 2017, Brain pathology.

Mutational analysis of primary central nervous system lymphoma

K. Hoang-Xuan, Y. Marie, A. Jouvet, 2014, Oncotarget.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

F. Ducray, O. Chinot, A. Idbaih, 2015, Neurology.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs

David T. W. Jones, R. Eils, M. Wolter, 2016, Cell.

Pineocytoma and Pineal Parenchymal Tumors of Intermediate Differentiation Presenting Cytologic Pleomorphism: A Multicenter Study

P. Varlet, A. Jouvet, D. Figarella-Branger, 2008, Brain pathology.

Subclinical Abnormal Gyration Pattern, a Potential Anatomic Marker of Epileptogenic Zone in Patients With Magnetic Resonance Imaging–Negative Frontal Lobe Epilepsy

P. Chauvel, D. Rivière, F. Bartolomei, 2011, Neurosurgery.

Patterns of care for 952 patients with newly diagnosed glioblastoma

H. Duffau, J. Honnorat, O. Chinot, 2008 .

New IDH1 I113T mutation associated with BRAF V600E mutation: New driver of gliomagenesis?

D. Figarella-Branger, E. Tabouret, F. Fina, 2014, Journal of the Neurological Sciences.

A TPM3 mutation causing cap myopathy

D. Figarella-Branger, J. Pouget, N. Monnier, 2009, Neuromuscular Disorders.

Histopathologic and Ultrastructural Features and Claudin Expression in Papillary Tumors of the Pineal Region: A Multicenter Analysis

P. Varlet, J. Ghersi-Egea, A. Jouvet, 2012, The American journal of surgical pathology.

Suprasellar granular-cell tumour, presenting with intraventricular haemorrhage.

D. Figarella-Branger, H. Dufour, P. Bouillot, 1995, British journal of neurosurgery.

Validation of the new glioma WHO classification in the french POLA network: Analysis of 1041 cases.

F. Ducray, A. Idbaih, A. Jouvet, 2016 .

Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023).

I. Fournier, F. Ducray, M. Sanson, 2023, Trends in cancer.

CCR 2 A and CCR 2 B , the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies

D. Figarella-Branger, J. Pellissier, M. Civatte, 2022 .

Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies.

D. Figarella-Branger, J. Pouget, J. Harlé, 2008, Arthritis and rheumatism.

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study.

L. Capelle, F. Ducray, J. Honnorat, 2022, Neuro-oncology.

Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling.

A. Jouvet, D. Figarella-Branger, C. Godfraind, 2016, Neuro-oncology.

Primary intradural Ewing’s sarcoma of the cauda equina presenting with acute bleeding

G. Caruso, D. Figarella-Branger, F. Vincentelli, 2010, Acta Neurochirurgica.